Bladder cancer incidence and risk factors in men with prostate cancer: results from Cancer of the Prostate Strategic Urologic Research Endeavor.

Bladder cancer incidence and risk factors in men with prostate cancer: results from Cancer of the Prostate Strategic Urologic Research Endeavor. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Bladder cancer incidence and risk factors in men with prostate cancer: results from Cancer of the Prostate Strategic Urologic Research Endeavor. Abstract Text:

Stephen Boorjian,Janet E Cowan,Badrinath R Konety,Janeen DuChane,Ashutosh Tewari,Peter R Carroll,Christopher J Kane, ,

PURPOSE: We evaluated a large disease registry to determine the incidence of bladder cancer in patients with prostate cancer and investigate whether the type of treatment for prostate cancer increased the risk of bladder cancer. MATERIALS AND METHODS: We analyzed the CaPSURE disease registry for men diagnosed with prostate cancer plus bladder cancer between 1989 and 2003. Demographics, comorbidities and prostate cancer treatment modalities were compared in patients with and without bladder cancer. A backward stepwise Cox proportional hazards regression model was used to predict bladder cancer onset after treatment for prostate cancer in patients who had bladder cancer 30 days or greater after prostate cancer treatment. RESULTS: Of 9,780 patients from CaPSURE 143 (1.46%) also had bladder cancer. Patients with bladder cancer and prostate cancer were older (p<0.01) and more likely to be white (p=0.03), and they had lower levels of income (p<0.01) and education (p=0.04) than patients with prostate cancer only. Comorbidities did not differ between patients with and without bladder cancer. Patients treated with radical prostatectomy were approximately half as likely to have posttreatment bladder cancer as patients who underwent radiation therapy (HR 0.51, 95% CI 0.29-0.89). Patients who smoked had an independent increase in the risk of bladder cancer (HR 2.08, 95% CI 1.09-3.97), while smokers treated with radiation therapy were at almost 4-fold risk for bladder cancer (HR 3.65, 95% CI 1.45-9.16). CONCLUSIONS: The incidence of bladder cancer in patients with prostate cancer was 1.5%. Radiation therapy and smoking increased the risk of bladder cancer.

Bladder cancer incidence and risk factors in men with prostate cancer: results from Cancer of the Prostate Strategic Urologic Research Endeavor. Publishing Authors By Initials

S Boorjian,JE Cowan,BR Konety,J DuChane,A Tewari,PR Carroll,CJ Kane, ,

For similar neoplasms: neoplasms by site: urogenital neoplasms: urologic neoplasms: urinary bladder neoplasms research abstracts see: neoplasms: neoplasms by site: urogenital neoplasms: urologic neoplasms: urinary bladder neoplasms research

PUBMED ID PMID:

MEDLINE DATE:

Bladder cancer incidence and risk factors in men with prostate cancer: results from Cancer of the Prostate Strategic Urologic Research Endeavor. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: The Journal of urology

VOLUME: 177

Page Numbers: 883-7; discussion 887-8

Journal Abbreviation: J. Urol.

ISSN: 0022-5347

DAY: 3

MONTH: Mar

YEAR: 2007

Bladder cancer incidence and risk factors in men with prostate cancer: results from Cancer of the Prostate Strategic Urologic Research Endeavor. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 376374

Bladder cancer incidence and risk factors in men with prostate cancer: results from Cancer of the Prostate Strategic Urologic Research Endeavor. Keywords Mesh Terms:

KEYWORDS: Urinary Bladder Neoplasms

MESH TERMS: epidemiology

Chemical & Substance for Abstract: Bladder cancer incidence and risk factors in men with prostate cancer: results from Cancer of the Prostate Strategic Urologic Research Endeavor. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Bladder cancer incidence and risk factors in men with prostate cancer: results from Cancer of the Prostate Strategic Urologic Research Endeavor.

AFFILIATION: Department of Urology, New York Presbyterian Hospital-Weill-Cornell Medical Center, New York, New York, USA.

Country: United States

AGENCY: United States PHS

GRANT: P50 C89520

ACRONYM:

MEDLINETA: J Urol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Bladder cancer incidence and risk factors in men with prostate cancer: results from Cancer of the Prostate Strategic Urologic Research Endeavor Related Publications

• 277.
• A modular, flexible training strategy to achieve competence in diagnostic and interventional musculoskeletal ultrasound in patients with hip osteoarthritis.
• A process to facilitate decision making in pediatric stem cell transplantation: the individualized care planning and coordination model.
• A role for N-cadherin in mesodermal morphogenesis during gastrulation.
• Advances and opportunities in assessing contaminant sensitivity of freshwater mussel (Unionidae) early life stages.
• Bladder cancer incidence and risk factors in men with prostate cancer: results from Cancer of the Prostate Strategic Urologic Research Endeavor.
• Demonstration of complex-conjugate-resolved harmonic Fourier-domain optical coherence tomography imaging of biological samples.
• Diploids heterozygous for a vma13Delta mutation in Saccharomyces cerevisiae highlight the importance of V-ATPase subunit balance in supporting vacuolar acidification and silencing cytosolic V1-ATPase activity.
• Editorial: schizophrenia international research society.
• Effects of body mass on nicotine-induced thermogenesis and catecholamine release in male smokers.
• Genomics and the future of pharmacotherapy in psychiatry.
• Geriatrics as a paradigm for good chronic care.
• Head injury - modern army combatives: 999: may 30 2:40 PM - 3:00 PM.
• Integer quantum Hall effect on a six-valley hydrogen-passivated silicon (111) surface.
• Laparoscopic Nissen fundoplication in an infant with situs inversus.
• Loss of vacuolar proton-translocating ATPase activity in yeast results in chronic oxidative stress.
• Metabolic risks and effects of atypical antipsychotic treatment.
• National survey of pediatric residency program directors and residents regarding education in palliative medicine and end-of-life care.
• Patient-reported outcomes in end-of-life research in pediatric oncology.
• RAVE is essential for the efficient assembly of the C subunit with the vacuolar H(+)-ATPase.
• Radiation medicine practice in the image-guided radiation therapy era: new roles and new opportunities.
• Raftlike polyvalent inhibitors of the anthrax toxin: modulating inhibitory potency by formation of lipid microdomains.
• Randomized comparison of olanzapine versus risperidone for the treatment of first-episode schizophrenia: 4-month outcomes.
• SV40 oncoproteins enhance asbestos-induced DNA double-strand breaks and abrogate senescence in murine mesothelial cells.
• Scaffolds based on degradable alginate hydrogels and poly(lactide-co-glycolide) microspheres for stem cell culture.
• Synthesis of potent inhibitors of anthrax toxin based on poly-L-glutamic acid.
• The contributions of strategy use to working memory span: a comparison of strategy assessment methods.
• The management of schizophrenia: safety, treatment, and continuity of care. Introduction.
• Treatment adherence and long-term outcomes.
• Ziprasidone-induced cognitive enhancement in schizophrenia: specificity or pseudospecificity?